-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Letter to the Editor: Patient-Driven Research
By Jill Feldman, EGFR Resisters Co-Founder Posted: December 11, 2019 Jill Feldman I was so glad to see the article by Dr. Amy Moore on PDX models in the October issue. As a Co-Founder of the EGFR Resisters, our collaboration with the GO2 Foundation for Lung Cancer is empowering patients to participate in studies that…
-
Dr. Richard Pazdur Discusses Project Facilitate and the Expanded-Access Program
Posted: December 11, 2019 In June 2019, the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence launched Project Facilitate, a call center that assists oncology healthcare professionals with the submission process involved in obtaining unapproved therapies for individual patients with cancer via the Expanded Access program.1 Richard Pazdur, MD, director of the FDA…
-
Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational Data
Posted: November 12, 2019 Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking PACIFIC data in new directions. Greg Durm, MD, is a medical oncologist at the Indiana University Simon Cancer Center and principal investigator of a phase II trial examining concurrent chemoradiation…
-
Experts Discuss Turnaround Times, Geographic Differences Regarding Liquid Biopsy
Improved Turnaround Times for Biopsy Results Matters More Than Type of Biopsy By Dr. Edgardo S. Santos Castillero, MD, FACP Posted: December 11, 2019 Dr. Edgardo S. Santos Castillero Regarding “Liquid Biopsy for Assessing Response or Progression in Advanced NSCLC” by Dr. Geoffrey R. Oxnard published in the October issue of the IASLC Lung Cancer News, I…
-
IASLC 2019 World Conference on Lung Cancer: Collaborative Formats, Novel Data
Posted: August 14, 2019 Dr. Ramon Rami-Porta The world’s largest international gathering of clinicians, researchers, and scientists in the field of lung cancer and thoracic oncology—the IASLC 2019 World Conference on Lung Cancer (WCLC)—will kick off on September 7, in Barcelona, Spain. As in previous years, more than 7,000 delegates representing more than 100 countries are…
-
Palliative Care: Combating Stigma and Enhancing Quality of Care – A Worldwide Perspective
By Corey J. Langer, MD, FACP Posted: December 11, 2019 Dr. Corey Langer Jennifer Temel, MD, and colleagues1 showed in a small but well-conducted phase III trial that a proactive, intensive palliative care program compared to our more typical reactive approach could lead to improved outcomes in advanced NSCLC, including better quality of life,…
-
Alice Shaw, MD
Posted: December 11, 2019 Alice Shaw, MD, has joined Novartis as the vice president, global head of Translational Clinical Oncology. Previously, Dr. Shaw was the director of Thoracic Oncology and the Paula O’Keeffe Endowed Chair in Thoracic Oncology at Massachusetts General Hospital, as well as a professor of medicine at Harvard Medical School. Dr. Shaw’s…
-
Stephen M. Hahn, MD, FASTRO
Posted: December 11, 2019 Stephen M. Hahn, MD, FASTRO, has been nominated to be the next commissioner of the U.S. Food and Drug Administration by President Trump. If approved by the Senate, Dr. Hahn will vacate his position as chief executive officer of The University of Texas MD Anderson Cancer Center, which he has held…
-
Smoking Cessation Prior to Lung Cancer Surgery
By Jessica Donington, MD, MSCR Posted: November 12, 2019 Dr. Jessica Donington Approximately 80% to 85% of patients undergoing lung cancer resections have a smoking history, and 20% are active smokers. Never smokers have improved short- and long-term outcomes following lung resection compared to those who have smoked. The value of smoking cessation prior to or…
-
Vassiliki Papadimitrakopoulou, MD
Posted: December 11, 2019 Vassiliki Papadimitrakopoulou, MD, has left The University of Texas MD Anderson Cancer Center, where she was a professor of medicine in the Department of Thoracic/Head and Neck Medical Oncology, to join Pfizer Oncology as the Clinical Development Leader. Dr. Papadimitrakopoulou is also a member of the FDA’s Oncologic Drugs Advisory Committee…
View ILCN Archives
Provider Resources
Popular Articles